These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19917541)

  • 1. Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.
    Bosch-Barrera J; Espinós J; Gómez-Ibáñez A; Gállego Pérez-Larraya J; Iriarte J
    Clin Transl Oncol; 2009 Nov; 11(11):765-7. PubMed ID: 19917541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
    Vahdat LT; Thomas ES; Roché HH; Hortobagyi GN; Sparano JA; Yelle L; Fornier MN; Martín M; Bunnell CA; Mukhopadhyay P; Peck RA; Perez EA
    Support Care Cancer; 2012 Nov; 20(11):2661-8. PubMed ID: 22382588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proactive management of adverse events maintains the clinical benefit of ixabepilone.
    Yardley DA
    Oncologist; 2009 May; 14(5):448-55. PubMed ID: 19411315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.
    LaPointe NE; Morfini G; Brady ST; Feinstein SC; Wilson L; Jordan MA
    Neurotoxicology; 2013 Jul; 37():231-9. PubMed ID: 23711742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
    Goodin S
    Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatological toxicity of ixabepilone.
    Conlin AK; Vahdat L
    Anticancer Res; 2006; 26(3B):2279-80. PubMed ID: 16821602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
    Lechleider RJ; Kaminskas E; Jiang X; Aziz R; Bullock J; Kasliwal R; Harapanhalli R; Pope S; Sridhara R; Leighton J; Booth B; Dagher R; Justice R; Pazdur R
    Clin Cancer Res; 2008 Jul; 14(14):4378-84. PubMed ID: 18628451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epothilone-induced peripheral neuropathy: a review of current knowledge.
    Argyriou AA; Marmiroli P; Cavaletti G; Kalofonos HP
    J Pain Symptom Manage; 2011 Dec; 42(6):931-40. PubMed ID: 21621965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixabepilone: a new active chemotherapy in the treatment of breast cancer.
    Villanueva C; Vuillemin AT; Demarchi M; Bazan F; Chaigneau L; Pivot X
    Womens Health (Lond); 2009 Mar; 5(2):115-21. PubMed ID: 19245349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
    Bhushan S; Walko CM
    Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
    Villanueva C; Dufresne A; Pivot X; Viel E
    Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone: a new microtubule-targeting agent for breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixabepilone.
    Stein A
    Clin J Oncol Nurs; 2010 Feb; 14(1):65-71. PubMed ID: 20118028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
    Denduluri N; Lee JJ; Walshe J; Berman AW; Vatas U; Chow CK; Steinberg SM; Cox MC; Low JA; Swain SM
    Invest New Drugs; 2007 Feb; 25(1):63-7. PubMed ID: 16933153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.